Almirall SA 2019 AR2
The report highlights Almirall's strong financial and operational performance in 2019, with total revenues increasing by 12% to ’908.4 million, driven by its medical dermatology strategy. The company made significant progress in its R&D pipeline, including the initiation of Phase III trials for Lebrikizumab and the filing of Tirbanibulin. On the sustainability front, Almirall reduced its greenhouse gas emissions (location-based) by 19% compared to 2014 and improved its Carbon Disclosure Project (CDP) rating to a B-Management level. Additionally, the company launched the Digital Garden accelerator to foster digital innovation in medical dermatology and successfully implemented flexible working initiatives for its employees.
Company: Almirall SA
Sector: Manufacturing
Country: Spain
Year: 2019
Type: AR2
Pages: 53
Almirall SA
The report highlights Almirall's strong financial and operational performance in 2019, with total revenues increasing by 12% to ’908.4 million, driven by its medical dermatology strategy. The company made significant progress in its R&D pipeline, including the initiation of Phase III trials for Lebrikizumab and the filing of Tirbanibulin. On the sustainability front, Almirall reduced its greenhouse gas emissions (location-based) by 19% compared to 2014 and improved its Carbon Disclosure Project (CDP) rating to a B-Management level. Additionally, the company launched the Digital Garden accelerator to foster digital innovation in medical dermatology and successfully implemented flexible working initiatives for its employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Total Waste
Employees